Skip to content

Novavax

US · NVAX #2865 by market cap Listed 1970
7.47 -0.25 -3.24%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Price chart

Pre-market 7.60 -1.55%
After-hours 7.55 +1.07%
Overnight 7.71 -0.13%
12.827.327.472026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on NVAX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +4.4% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 28.1% of float.
  • Analyst tilt is Hold.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days C → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation D

How expensive the stock is versus earnings, sales and its own 5-year history.

Forward P/E 92.1x Better than 3%
Price / Sales 3.4x Better than 36%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability B

How much profit the business keeps from each dollar of sales and capital.

Gross margin 93.5% Better than 98%
Operating margin 49.0% Better than 98%
Net margin 39.2% Better than 95%
Return on equity -1,265.7% Better than 1%
Return on invested capital -286.9% Better than 0%
Momentum C+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -16.4% Better than 37%
6-month return -18.9% Better than 28%
12-month return (ex latest month) 49.9% Better than 83%
Distance below 52-week high 44.2% Better than 24%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.1x Better than 59%
Debt to assets 21.1% Better than 54%
Interest coverage 20.6x Better than 83%
Analyst View B

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 60.0% Better than 36%
Upside to average target 82.1% Better than 79%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -12.43%
1M -34.65%
3M -11.28%
6M -19.42%
YTD +11.16%
1Y +20.10%
3Y +31.05%
5Y -96.12%

Key statistics

Price & volume

Prev close
7.72
Open
7.59
Day range
7.43 - 7.98
Avg price
7.64
Volume
4.74M
Turnover
36.19M
Amplitude
7.12%
52-week range
6.36 - 13.39

Valuation

P/E
2.90
P/E (TTM)
-14.37
P/B
-5.68
EPS
2.58
Net profit
425.72M
Net assets
-216.82M

Share structure

Market cap
1.23B
Float cap
1.09B
Shares out
165.01M
Float shares
146.28M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 16% of range
6.36 13.39

44.2% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-24.21M net over the window

Short interest

Shares short
46.33M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Novavax (NVAX)?

Novavax last traded at 7.47. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Novavax's market cap?

About 1.23B.

What is the P/E ratio of Novavax?

The trailing twelve-month P/E is -14.37. The Valuation tab shows it against the stock's own five-year range.

Does Novavax pay a dividend?

Novavax does not currently pay a regular dividend.

Is Novavax a buy according to analysts?

The consensus of 5 analysts is a Hold rating, with an average 12-month price target of 13.60, which implies 82.1% upside from the current price. This is not investment advice.

What is Novavax's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Novavax a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:01:36 · For reference only, not investment advice and not tailored to your situation.

Novavax discussion 0 comments

Add a comment